



Data Indicate That SuperGen's Lead JAK2 Kinase Inhibitors Prevent Cancer Cell Proliferation in Non-clinical Models

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced the presentation of data that describe how its lead JAK2 kinase inhibitors prevent cancer cell proliferation in non-clinical models (Poster 779, Abstract 3560). This data is part of a series of presentations at the American Society of Hematology's 49th Annual Meeting taking place at the Georgia World Congress Center in Atlanta.

Entitled "Targeting the JAK2 in Hematological Malignancies," the poster described how SuperGen used its CLIMB™ technology to build several models that were utilized for screening 2.3 million virtual small molecule compounds. This process generated a subset of leads that were screened using in silico algorithms to identify "druggable" candidates to pursue. Testing of the lead candidates in treated leukemia cell cultures indicated that the JAK2 kinase inhibitors were active against both wild-type and mutant JAK2 kinase activity and caused potent inhibition of cancer cell proliferation.

"Our JAK2 kinase inhibitor program is a good example of how we deploy our CLIMB™ drug discovery process to identify and optimize pre-clinical drug candidates," said Dr. Gregory Berk, SuperGen's Chief Medical Officer. "This proprietary process allows us to rapidly enter pre-clinical testing with drug candidates. The in vitro inhibition of cancer cell proliferation by our lead JAK2 kinase inhibitors demonstrates the promise that this program holds to treat both hematological cancers and solid tumors."

A copy of the poster presentation will be available in the pipeline section of SuperGen's Web site www.supergen.com.

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit <http://www.supergen.com>.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns
SuperGen, Inc.
SVP, Corporate Communications & Business Development
Tel: (925) 560-0100
E-mail: tenns@supergen.com

Mary M. Vegh
SuperGen, Inc.
Manager, Investor Relations
Tel: (925) 560-2845
E-mail: mary.vegh@supergen.com

SOURCE SuperGen Inc.

CONTACT: Timothy L. Enns, SVP, Corporate Communications & Business Development, +1-925-560-0100,
tenns@supergen.com,

or

Mary M. Vegh, Manager, Investor Relations, +1-925-560-2845, mary.vegh@supergen.com, both of SuperGen, Inc.

Web site: <http://www.supergen.com>